Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
To evaluate the efficacy and safety of bendamustine combined with chidamide and lenalidomide in R/R PTCL patients.
Trial Details
- NCT ID
- NCT07072221
- Phase
- NA
- Sponsor
- The First Affiliated Hospital of Soochow University
- Status
- RECRUITING
- Cancer Type
- T-Cell Lymphoma Lymphoma
- Interventions
- BCL regimen
- Cohort 1 (ASCT-eligible)
- Cohort 2 (ASCT--ineligible)
- Locations (sample)
- Suzhou, Jiangsu, China|31.30408,120.59538
Key Eligibility Criteria
- Age ≥18 years, male or female not limited;
- Patients must have the capacity to understand and willingly provide written informed consent;
- ECOG score 0-3 points;
- Expected lifespan\>3 months;
For full eligibility, visit ClinicalTrials.gov.